A biochemical approach to understand the pathogenesis of advanced pulmonary arterial hypertension: Metabolomic profiles of arginine, sphingosine-1-phosphate, and heme of human lung

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Zhao, Yidan D ^a   Chu, Lei ^a   Lin, Kathleen ^a   Granton, Elise ^a   Yin, Li ^a   Peng, Jenny ^a   Hsin, Michael ^a   Wu, Licun ^a   Yu, Amy ^a   Waddell, Thomas ^a   Keshavjee, Shaf ^a   Granton, John ^b   De Perrot, Marc ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HEME; NITRIC OXIDE; SPHINGOSINE 1 PHOSPHATE; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GAS CHROMATOGRAPHY; HEART RIGHT VENTRICLE FAILURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LOBECTOMY; LUNG PARENCHYMA; MALE; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; PATHOGENESIS; PULMONARY HYPERTENSION; SCHOOL CHILD; VASCULAR REMODELING; ANALOGS AND DERIVATIVES; LUNG; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; ARGININE; FEMALE; HEME; HUMANS; HYPERTENSION, PULMONARY; LUNG; LYSOPHOSPHOLIPIDS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MIDDLE AGED; NITRIC OXIDE; SPHINGOSINE; VASCULAR REMODELING;

EID: 84943328681     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134958     Document Type: Article

References (42)

1. Galie N, Simonneau G (2014) [The Fifth World Symposium on Pulmonary Hypertension]. Turk Kardiyol Dern Ars 42 Suppl 1:1-4. PMID: 25697029
2. Fessel JP, Hamid R, Wittmann BM, Robinson LJ, Blackwell T, Tada Y, et al. (2012) Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ 2:201-213. doi: 10.4103/2045-8932.97606 PMID: 22837861
3. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla K. N. et al. (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65:613-621. PMID: 15695406
4. Zhao Y, Peng J, Lu C, Hsin M, Mura M, Wu L. et al. (2014) Metabolomic heterogeneity of pulmonary arterial hypertension. PLoS One 9:e88727. doi: 10.1371/journal.pone.0088727 PMID: 24533144
5. Tuder RM, Davis LA, Graham BB (2012) Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med 185:260-266. doi: 10. 1164/rccm.201108-1536PP PMID: 22077069
6. Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes A. R. (2011) Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant 30:904-911. doi: 10.1016/j.healun. 2011.02.016 PMID: 21493097
7. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L. et al. (2007) Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptorgamma activation. Circulation 115:1275-1284. PMID: 17339547
8. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson E. C. et al. (2010) Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 121:2661-2671. doi: 10.1161/CIRCULATIONAHA.109.916098 PMID: 20529999
9. Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Dyck J. R. et al. (2010) Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med 2:44ra58. doi: 10.1126/scitranslmed.3001327 PMID: 20702857
10. Hassoun PMMMea, Barnett CF (2013) 5th World Symposium of Pulmonary Hypertension, Nice.
11. Takeda Y, Takeda Y, Tomimoto S, Tani T, Narita H, Kimura G. (2010) Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. BMC Pulm Med 10:22. doi: 10.1186/1471-2466-10-22 PMID: 20412580
12. Gillespie MN, Olson JW (2010) Polyamine regulatory pathways as pharmacologic targets in pulmonary arterial hypertension. Adv Exp Med Biol 661:375-389. doi: 10.1007/978-1-60761-500-2-24 PMID: 20204743
13. Zuckerbraun BS, George P, Gladwin MT (2011) Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. Cardiovasc Res 89:542-552. doi: 10.1093/cvr/cvq370 PMID: 21177703
14. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Thunnissen F. B. et al. (2004) Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 18:1746-1748. PMID: 15364894
15. Kepka-Lenhart D, Mistry SK, Wu G, Morris SM Jr. (2000) Arginase I: a limiting factor for nitric oxide and polyamine synthesis by activated macrophages? Am J Physiol Regul Integr Comp Physiol 279:R2237-2242. PMID: 11080091
16. Mori M, Gotoh T (2004) Arginine metabolic enzymes, nitric oxide and infection. J Nutr 134:2820S-2825S; discussion 2853S. PMID: 15465793
17. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Yaici A. et al. (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122:156-163. doi: 10.1161/CIRCULATIONAHA.109.911818 PMID: 20585011
18. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Brovkovych V. et al. (2009) Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest 119:2009-2018. doi: 10.1172/JCI33338 PMID: 19487814
19. Balint B, Kharitonov SA, Hanazawa T, Donnelly LE, Shah PL, Hodson M. E. et al. (2001) Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis. Eur Respir J 17:1201-1207. PMID: 11491165
20. Closs EI (2002) Expression, regulation and function of carrier proteins for cationic amino acids. Curr Opin Nephrol Hypertens 11:99-107. PMID: 11753094
21. Simon PM, Pachence J, Belinka B, Poiani GJ, Lu SE, Tozzi C. A. et al. (2006) Prodrug of proline analogue reduces hypoxic pulmonary hypertension in rats. Pulm Pharmacol Ther 19:242-250. PMID: 16150622
22. Poiani GJ, Tozzi CA, Choe JK, Yohn SE, Riley DJ (1990) An antifibrotic agent reduces blood pressure in established pulmonary hypertension in the rat. J Appl Physiol (1985) 68:1542-1547.
23. Kerr JS, Ruppert CL, Tozzi CA, Neubauer JA, Frankel HM, Yu S. Y. et al. (1987) Reduction of chronic hypoxic pulmonary hypertension in the rat by an inhibitor of collagen production. Am Rev Respir Dis 135:300-306. PMID: 3813190
24. Thomas M (2010) Pharmacological targets for pulmonary vascular disease: vasodilation versus antiremodelling. Adv Exp Med Biol 661:475-490. doi: 10.1007/978-1-60761-500-2-31 PMID: 20204750
25. Kliment CR, Englert JM, Crum LP, Oury TD (2011) A novel method for accurate collagen and biochemical assessment of pulmonary tissue utilizing one animal. Int J Clin Exp Pathol 4:349-355. PMID: 21577320
26. Yang C, Park AC, Davis NA, Russell JD, Kim B, Brand D. D. et al. (2012) Comprehensive mass spectrometric mapping of the hydroxylated amino acid residues of the alpha1 (V) collagen chain. J Biol Chem 287:40598-40610. doi: 10.1074/jbc. M112.406850 PMID: 23060441
27. Adams E, Frank L (1980) Metabolism of proline and the hydroxyprolines. Annu Rev Biochem 49:1005-1061. PMID: 6250440
28. Couttas TA, Kain N, Daniels B, Lim XY, Shepherd C, Kril J. et al. (2014) Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. Acta Neuropathol Commun 2:9. doi: 10.1186/2051-5960-2-9 PMID: 24456642
29. Kajiwara K, Muneoka T, Watanabe Y, Karashima T, Kitagaki H, Funato K. (2012) Perturbation of sphingolipid metabolism induces endoplasmic reticulum stress-mediated mitochondrial apoptosis in budding yeast. Mol Microbiol 86:1246-1261. doi: 10.1111/mmi.12056 PMID: 23062268
30. Maceyka M, Spiegel S (2014) Sphingolipid metabolites in inflammatory disease. Nature 510:58-67. doi: 10.1038/nature13475 PMID: 24899305
31. Airola MV, Hannun YA (2013) Sphingolipid metabolism and neutral sphingomyelinases. Handb Exp Pharmacol: 57-76. doi: 10.1007/978-3-7091-1368-4-3 PMID: 23579449
32. Russo SB, Ross JS, Cowart LA (2013) Sphingolipids in obesity, type 2 diabetes, and metabolic disease. Handb Exp Pharmacol: 373-401. doi: 10.1007/978-3-7091-1511-4-19 PMID: 23563667
33. Delgado A, Fabrias G, Bedia C, Casas J, Abad JL (2012) Sphingolipid modulation: a strategy for cancer therapy. Anticancer Agents Med Chem 12:285-302. PMID: 21864240
34. Ryland LK, Fox TE, Liu X, Loughran TP, Kester M (2011) Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther 11:138-149. PMID: 21209555
35. Chen J, Tang H, Sysol JR, Moreno-Vinasco L, Shioura KM, Chen T. et al. (2014) The Sphingosine Kinase 1/Sphingosine-1-Phosphate Pathway in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med.
36. Abbasi T, Garcia JG (2013) Sphingolipids in lung endothelial biology and regulation of vascular integrity. Handb Exp Pharmacol: 201-226. doi: 10.1007/978-3-7091-1511-4-10 PMID: 23563658
37. Oo ML, Chang SH, Thangada S, Wu MT, Rezaul K, Blaho V. et al. (2011) Engagement of S1P (1)-degradative mechanisms leads to vascular leak in mice. J Clin Invest 121:2290-2300. doi: 10.1172/JCI45403 PMID: 21555855
38. Brittain EL, Janz DR, Austin ED, Bastarache JA, Wheeler LA, Ware L. B. et al. (2014) Elevation of plasma cell-free hemoglobin in pulmonary arterial hypertension. Chest 146:1478-1485. doi: 10.1378/chest.14-0809 PMID: 24945582
39. Fox CJ, Bowman JN (2011) Advances in resuscitation in the setting of vascular injury. Perspect Vasc Surg Endovasc Ther 23:112-116. doi: 10.1177/1531003511400627 PMID: 21502108
40. Wood KC, Hsu LL, Gladwin MT (2008) Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med 44:1506-1528. doi: 10.1016/j.freeradbiomed.2008.01.008 PMID: 18261470
41. Tenhunen R, Marver HS, Schmid R (1968) The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A 61:748-755. PMID: 4386763
42. Sarady-Andrews JK, Liu F, Gallo D, Nakao A, Overhaus M, Ollinger R. et al. (2005) Biliverdin administration protects against endotoxin-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol 289:L1131-1137. PMID: 16155084